Preferred Label : abrocitinib;

MeSH Hyperonym : N-(cis-3-(Methyl(7H-pyrrolo(2,3-d)pyrimidin-4-yl)amino)cyclobutyl)-propane-1-sulfonamide; 1-Propanesulfonamide, N-(cis-3-(methyl-7H-pyrrolo(2,3-d)pyrimidin-4-ylamino)cyclobutyl)-;

UNII : 73SM5SF3OR;

Détails


Consulter ci-dessous une sélection des principales ressources :

Vous pouvez consulter :


https://www.has-sante.fr/jcms/p_3482873/fr/cibinqo-abrocitinib-dermatite-atopique-da
2024
false
false
false
France
abrocitinib
treatment outcome
insurance, health, reimbursement
Janus Kinase Inhibitors
administration, oral
adult
evaluation of the transparency committee
dermatitis, atopic
abrocitinib

---
https://www.has-sante.fr/jcms/p_3538222/fr/cibinqo-abrocitinib-dermatite-atopique-des-12-ans
2024
false
false
false
France
adolescent
treatment outcome
insurance, health, reimbursement
Janus Kinase Inhibitors
administration, oral
abrocitinib
evaluation of the transparency committee
dermatitis, atopic
abrocitinib

---
https://ansm.sante.fr/tableau-marr/abrocitinib
2023
false
false
false
France
French
risk management
abrocitinib
abrocitinib
administration, oral
Drug-Related side effects and adverse reactions
guidelines for drug use
patient education handout

---
https://www.has-sante.fr/jcms/p_3325534/fr/cibinqo-abrocitinib
2022
false
false
false
France
insurance, health, reimbursement
treatment outcome
abrocitinib
dermatitis, atopic
adult
Janus Kinase Inhibitors
pregnancy
teratogens
abrocitinib
continuity of patient care
guidelines for drug use
administration, oral
evaluation of the transparency committee
abrocitinib

---
https://www.ema.europa.eu/en/medicines/human/EPAR/cibinqo
2022
false
false
false
Netherlands
French
abrocitinib
abrocitinib
abrocitinib
summary of product characteristics
package leaflet
syndication feed
drug evaluation
drug approval
europe
treatment outcome
Janus Kinase Inhibitors
Janus Kinase Inhibitors
adult
dermatitis, atopic
administration, oral
continuity of patient care
product surveillance, postmarketing
aged
drug interactions
pregnancy
breast feeding
janus kinase 1
drug evaluation, preclinical
Tyrosine Kinase Inhibitors

---
Nous contacter.
27/07/2025


[Accueil] [Haut de page]

© CHU de Rouen. Toute utilisation partielle ou totale de ce document doit mentionner la source.